Amgen, Inc. (AMGN)
403.04
-4.23
(-1.04%)
USD |
NASDAQ |
Oct 02, 16:00
403.83
+0.79
(+0.20%)
After-Hours: 20:00
Amgen Enterprise Value : 261.20B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 261.20B |
| October 01, 2026 | 263.49B |
| September 30, 2026 | 271.18B |
| September 29, 2026 | 272.33B |
| September 28, 2026 | 269.36B |
| September 25, 2026 | 267.45B |
| September 24, 2026 | 262.82B |
| September 23, 2026 | 262.85B |
| September 22, 2026 | 265.09B |
| September 21, 2026 | 255.86B |
| September 18, 2026 | 251.80B |
| September 17, 2026 | 248.62B |
| September 16, 2026 | 246.77B |
| September 15, 2026 | 246.39B |
| September 14, 2026 | 249.55B |
| September 11, 2026 | 247.31B |
| September 10, 2026 | 250.08B |
| September 09, 2026 | 254.84B |
| September 08, 2026 | 255.86B |
| September 04, 2026 | 279.68B |
| September 03, 2026 | 283.41B |
| September 02, 2026 | 282.71B |
| September 01, 2026 | 280.16B |
| August 31, 2026 | 275.71B |
| August 28, 2026 | 277.08B |
| Date | Value |
|---|---|
| August 27, 2026 | 279.55B |
| August 26, 2026 | 281.36B |
| August 25, 2026 | 282.39B |
| August 24, 2026 | 283.25B |
| August 21, 2026 | 280.82B |
| August 20, 2026 | 277.79B |
| August 19, 2026 | 282.45B |
| August 18, 2026 | 273.22B |
| August 17, 2026 | 270.03B |
| August 14, 2026 | 267.78B |
| August 13, 2026 | 269.20B |
| August 12, 2026 | 268.30B |
| August 11, 2026 | 267.29B |
| August 10, 2026 | 268.85B |
| August 07, 2026 | 265.47B |
| August 06, 2026 | 262.18B |
| August 05, 2026 | 263.79B |
| August 04, 2026 | 254.16B |
| August 03, 2026 | 248.13B |
| July 31, 2026 | 251.53B |
| July 30, 2026 | 252.87B |
| July 29, 2026 | 252.87B |
| July 28, 2026 | 255.82B |
| July 27, 2026 | 246.72B |
| July 24, 2026 | 246.60B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 200.90B |
| Regeneron Pharmaceuticals, Inc. | 70.72B |
| AbbVie, Inc. | 528.72B |
| Biogen, Inc. | 39.55B |
| Vertex Pharmaceuticals, Inc. | 121.99B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.375B |
| Revenue (Quarterly) | 10.07B |
| Total Expenses (Quarterly) | 7.692B |
| EPS Diluted (Quarterly) | 4.366 |
| Gross Profit Margin (Quarterly) | 72.08% |
| Profit Margin (Quarterly) | 23.59% |
| Earnings Yield | 3.99% |
| Operating Earnings Yield | 5.81% |
| Normalized Earnings Yield | 4.377 |